AGENUS INC Sublease Income
AGENUS INC (AGEN) reported Sublease Income of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2025-03-17
- AGENUS INC sublease income for the quarter ending 2020-12-31 was $146.00K, a 4.29% increase year-over-year.
- AGENUS INC sublease income for the quarter ending 2020-09-30 was $144.00K, a 2.86% increase year-over-year.
- AGENUS INC sublease income for the quarter ending 2020-06-30 was $144.00K, a 2.86% increase year-over-year.
- AGENUS INC sublease income for the quarter ending 2020-03-31 was $144.00K, a 2.86% increase year-over-year.
- AGENUS INC sublease income for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- AGENUS INC sublease income for fiscal 2022 was $613.00K, a 3.03% increase from fiscal 2021.
- AGENUS INC sublease income for fiscal 2021 was $595.00K, a 2.94% increase from fiscal 2020.
- AGENUS INC sublease income for fiscal 2020 was $578.00K, a 3.03% increase from fiscal 2019.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2022-12-31 | $613.00K 10-K · filed 2025-03-17 | |||
| 2021-12-31 | $595.00K 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $290.00K derived: sum of 2 quarters · filed 2023-03-16 | $434.00K derived: sum of 3 quarters · filed 2023-03-16 | $578.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | $144.00K 10-Q · filed 2020-11-09 | $288.00K derived: sum of 2 quarters · filed 2020-11-09 | $432.00K 10-Q · filed 2020-11-09 | $572.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $144.00K 10-Q · filed 2020-08-10 | $288.00K 10-Q · filed 2020-08-10 | $428.00K derived: sum of 3 quarters · filed 2022-03-01 | $568.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $144.00K 10-Q · filed 2020-05-11 | $284.00K derived: sum of 2 quarters · filed 2022-03-01 | $424.00K derived: sum of 3 quarters · filed 2022-03-01 | $564.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $280.00K derived: sum of 2 quarters · filed 2022-03-01 | $420.00K derived: sum of 3 quarters · filed 2022-03-01 | $561.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $140.00K 10-Q · filed 2020-11-09 | $280.00K derived: sum of 2 quarters · filed 2020-11-09 | $421.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $140.00K 10-Q · filed 2020-08-10 | $280.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $140.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |